Tradjenta

Type: Product
Name: Tradjenta
Publicerad Sep 24 2014 - uppdaterad Sep 25 2014 - 1 rapporter

Contrave Weight-Management Drug Receives FDA Approval

Twitter summary: FDA approves Contrave weight management drug, with potential future use in #T2DOn September 10, the FDA announced the approval of Orexigen’s weight management drug Contrave (naltrexone/bupropion combination). Orexigen had initially submitted ... [Published diaTribe - Sep 24 2014]
Publicerad Sep 24 2014 - uppdaterad Sep 24 2014 - 1 rapporter

BI/Lilly Launch Jardiance for Type 2 Diabetes – Now the Third Commercially Available SGLT-inhibitor in the US

Twitter summary: BI/Lilly launch Jardiance in the US, making it the 3 rd SGLT-2 inhibitor on the market; savings program for one-year free supplyAfter its recent FDA approval on August 1 , Jardiance (empagliflozin) is now commercially available in the ... [Published diaTribe - Sep 24 2014]
Publicerad Sep 19 2014 - uppdaterad Sep 19 2014 - 1 rapporter

Eli Lilly's Trulicity Approved by FDA for Type II Diabetes

Eli Lilly and Company ( LLY - Analyst Report ) received good news when the FDA approved its new injectable diabetes treatment, Trulicity, for adults suffering from type II diabetes.Trulicity, a glucagon-like peptide-1 (GLP-1) receptor, has been approved ... [Published Zacks.com - Sep 19 2014]
Publicerad Sep 19 2014 - uppdaterad Sep 19 2014 - 1 rapporter

Merck's weekly DPP-IV on par with daily Januvia: study

Share this article:With Januvia's patent up in 2022, Merck is preparing to replace its revenueFirst results from Phase-III tests of Merck's weekly type 2 diabetes medication omarigliptin showed patients did as well with 25mg of the experimental medication ... [Published Medical Marketing And Media - Sep 19 2014]
Publicerad Aug 06 2014 - uppdaterad Aug 06 2014 - 1 rapporter

Lilly and BI Close In On Diabetes Market Lead

With the recent approval of Jardiance in the US, Eli Lilly and partner Boehringer Ingelheim (BI) “have taken another step towards owning the most comprehensive diabetes portfolio in the industry”, according to research and consulting firm GlobalData ... [Published Pharmaceutical Executive - Aug 06 2014]
Publicerad Jul 24 2014 - uppdaterad Jul 24 2014 - 1 rapporter

TRADJENTA (Linagliptin) Tablet, Film Coated [Cardinal Health]

Publicerad Jul 22 2014 - uppdaterad Jul 22 2014 - 1 rapporter

TRADJENTA (Linagliptin) Tablet, Film Coated [Cardinal Health]

Publicerad Jun 17 2014 - uppdaterad Jun 17 2014 - 1 rapporter

Two phase III trials of empagliflozin/linagliptin combo tablet showed reduction in blood glucose levels in adults withT2D

Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company ... [Published PharmaBiz - Jun 17 2014]

Citat

...0 per cent with the combination," said Christophe Arbet-Engels, vice president, metabolic clinical development and medical affairs, BIPI. "People with type 2 diabetes must often take more than one medication to adequately control their blood sugar levels. If approved, this combination tablet with two mechanisms of action that lower A1C through different pathways in a single pill could be an important treatment option for physicians and patients."
...said Christophe Arbet-Engels, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Adults living with type 2 diabetes often take more than one therapy to manage their condition, and we hope the combination of these two products will help them improve control of their blood sugar."

Mer innehåll

Alla (13) | Nyheter (11) | Rapporter (0) | Bloggar (2) | Ljud/Video (0) | Faktablad (0) | Pressreleaser (0)
sort by: Date | Relevance
Contrave Weight-Management Drug Receives FDA Ap... [Published diaTribe - Sep 24 2014]
BI/Lilly Launch Jardiance for Type 2 Diabetes –... [Published diaTribe - Sep 24 2014]
Eli Lilly's Trulicity Approved by FDA for Type ... [Published Zacks.com - Sep 19 2014]
Merck's weekly DPP-IV on par with daily Januvia... [Published Medical Marketing And Media - Sep 19 2014]
Lilly and BI Close In On Diabetes Market Lead [Published Pharmaceutical Executive - Aug 06 2014]
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 24 2014]
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 22 2014]
Two phase III trials of empagliflozin/linaglipt... [Published PharmaBiz - Jun 17 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
What Do Pharma's "High Performers" Have in Common? [Published Pharmaceutical Executive - Mar 07 2014]
The New Metrics of Market Success [Published Pharmaceutical Executive - Mar 03 2014]
Januvia Pancreatic Cancer Allegations Help: Res... [Published PRWeb - Feb 27 2014]
Januvia Pancreatic Cancer Allegations Alert: Re... [Published PRWeb - Jan 19 2014]
1
Nyhetsvolym
Document Volume
Nätverk
Network

Bloggar

sort by: Date | Relevance
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 24 2014]
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 22 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.